Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$30.14
+2.5%
$28.30
$25.56
$36.45
$4.98B0.531.74 million shs1.53 million shs
Incyte Corporation stock logo
INCY
Incyte
$86.52
+0.6%
$75.78
$53.56
$87.99
$16.88B0.751.86 million shs645,297 shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$138.09
-2.7%
$131.81
$84.23
$154.61
$13.70B0.281.23 million shs465,947 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$387.44
-4.3%
$301.33
$266.98
$436.95
$17.52B0.62547,842 shs650,173 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.48%+1.45%+10.73%-6.79%+3.34%
Incyte Corporation stock logo
INCY
Incyte
+1.62%+2.36%+13.75%+27.53%+30.95%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
+1.66%+3.71%+10.09%+13.97%+11.70%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
+32.83%+30.91%+37.56%+24.95%+11.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alkermes plc stock logo
ALKS
Alkermes
4.8288 of 5 stars
4.42.00.04.23.12.51.9
Incyte Corporation stock logo
INCY
Incyte
4.72 of 5 stars
2.22.00.02.84.03.34.4
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.8627 of 5 stars
3.42.00.02.94.12.53.8
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
4.3912 of 5 stars
2.31.00.04.63.53.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.85
Moderate Buy$41.3137.08% Upside
Incyte Corporation stock logo
INCY
Incyte
2.33
Hold$81.60-5.69% Downside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.86
Moderate Buy$159.5015.50% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$412.696.52% Upside

Current Analyst Ratings Breakdown

Latest ALKS, UTHR, NBIX, and INCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$295.00 ➝ $414.00
9/2/2025
Alkermes plc stock logo
ALKS
Alkermes
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
9/2/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$432.00 ➝ $564.00
9/2/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$314.00 ➝ $463.00
8/22/2025
Incyte Corporation stock logo
INCY
Incyte
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$67.00 ➝ $73.00
8/14/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
8/13/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$385.00 ➝ $415.00
8/6/2025
Incyte Corporation stock logo
INCY
Incyte
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$67.00 ➝ $89.00
8/1/2025
Incyte Corporation stock logo
INCY
Incyte
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$90.00
8/1/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$165.00 ➝ $175.00
7/31/2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$425.00 ➝ $400.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.56B3.19$2.76 per share10.93$9.84 per share3.06
Incyte Corporation stock logo
INCY
Incyte
$4.24B3.98$0.57 per share152.84$21.36 per share4.05
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.36B5.81$3.34 per share41.30$27.17 per share5.08
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.08B5.68$36.11 per share10.73$159.04 per share2.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$367.07M$2.0814.4922.001.6723.15%24.86%17.14%10/23/2025 (Estimated)
Incyte Corporation stock logo
INCY
Incyte
$32.62M$4.4019.6513.230.6618.99%21.99%14.43%11/4/2025 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$341.30M$3.3840.8621.341.0113.88%13.22%9.39%10/29/2025 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.20B$25.6215.1614.094.6240.36%18.73%16.49%10/29/2025 (Estimated)

Latest ALKS, UTHR, NBIX, and INCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$0.98$1.06+$0.08$1.06$653.09 million$687.50 million
7/30/2025Q2 2025
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.80$6.41-$0.39$6.41$802.13 million$798.60 million
7/29/2025Q2 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.42$0.52+$0.10$0.52$343.20 million$390.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
N/A
3.23
2.85
Incyte Corporation stock logo
INCY
Incyte
0.01
2.85
2.78
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
3.20
3.10
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
7.26
6.94

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Incyte Corporation stock logo
INCY
Incyte
96.97%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.40%
Incyte Corporation stock logo
INCY
Incyte
17.80%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.30%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
10.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
1,800165.08 million157.82 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,617195.28 million160.52 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
1,80099.18 million94.92 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,30545.11 million40.46 millionOptionable

Recent News About These Companies

United Therapeutics rises 42.1%
United Thera Phase III win for Tyvaso
United Therapeutics (NASDAQ:UTHR) Price Target Raised to $564.00
United Therapeutics shares jump on positive lung disease study results
Why Is United Therapeutics Stock Rallying On Tuesday?
United Therapeutics Announces Positive TETON-2 Study Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alkermes stock logo

Alkermes NASDAQ:ALKS

$30.14 +0.74 (+2.50%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Incyte stock logo

Incyte NASDAQ:INCY

$86.52 +0.54 (+0.63%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$138.09 -3.83 (-2.70%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$387.44 -17.38 (-4.29%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.